Hansoh Pharmaceutical Group Company Limited (HK:3692) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Hansoh Pharmaceutical Group has received approval from China’s National Medical Products Administration to conduct clinical trials for its new antibody-drug conjugate, HS-20110, aimed at treating advanced solid tumors. This development marks a significant step in the company’s innovation efforts, potentially impacting its market position.
For further insights into HK:3692 stock, check out TipRanks’ Stock Analysis page.